Log in to search using one of your social media accounts:


IRRAS Strengthens Executive and Commercial Teams with Appointments of Karl-Matthias Moehlmann and Klemens Fölling

LA JOLLA, Calif., LAICHINGEN, Germany and STOCKHOLM, Sept. 13, 2017 -- (Healthcare Sales &Marketing Network) -- IRRAS, a commercial-stage medical technology company developing breakthrough devices for a broad range of intracranial bleeding applications a... Devices, Neurology, Personnel IRRAS, IRRAflow, stroke, intracranial pressure
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Eggs have been a taboo food for decades, since they are high in cholesterol, but the latest science suggests that they might not be as unhealthy as once thought. In a study published in the journal Heart, researchers from China found that people who ate an average of one egg per day had lower rates of heart disease and an even lower risk of having a bleeding stroke than people who did not eat eggs. The study included nearly half a million people in China who filled out questionnaires about their egg-eating habits and were followed for nine years on average for heart-related health events. People who said they ate eggs da...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Diet/Nutrition healthytime Source Type: news
The FDA today released a recall notice for a select number of Medtronic (NYSE:MDT) MindFrame Capture LP revascularization devices over issues with the delivery wire breaking or separating during use. The federal watchdog labeled the recall as a Class I, its most serious class of recall, which indicates the potential for serious injury or death. The Fridley, Minn.-based company’s MindFrame Capture LP device is designed to restore blood flow and remove blood clots within a blood vessel in the brain during acute ischemic stroke in patients who are ineligible or fail intravenous tissue plasminogen activator therapy. Medt...
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Neurological Recalls Vascular Medtronic Source Type: news
AbstractAtrial fibrillation (AF) occurs approximately in 3% of general population, with greater prevalence in elderly. Non-vitamin K-dependent oral anticoagulant agents (NOACs) according to the current European guidelines are recommended for patients with AF at high risk for stroke as a first-choice treatment. NOACs are not inferior to warfarin or some of them are better than warfarin in reducing the rate of ischemic stroke. Moreover, they significantly reduce the rate of intracranial hemorrhages, major bleedings, and mortality compared with warfarin. Nevertheless according to ESC guidelines, NOACs are not recommended in p...
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
AbstractContinuous flow left ventricular assist devices (CF-LVAD) require therapeutic anticoagulation which is often interrupted for procedures or bleeding. Prior to the availability of four factor prothrombin complex concentrate (4F-PCC) in the United States, warfarin was held and its effects reversed by vitamin K or fresh frozen plasma. We evaluated the use of 4F-PCC for temporary warfarin reversal in patients with CF-LVADs and assessed outcomes. This analysis is a retrospective study of CF-LVAD patients who received 4F-PCC for warfarin reversal in the setting of bleeding or need for urgent or elective procedures. Primar...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Authors: Kohsaka S, Katada J, Saito K, Terayama Y Abstract OBJECTIVE: To investigate the risk of bleeding events and stroke/systemic embolism (SE) among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial dosage of apixaban and patient age. METHODS: This retrospective cohort study used de-identified electronic health records-based claims data from 314 acute-care hospitals in Japan. NVAF patients newly initiated on warfarin or apixaban, with no prescription during the 180-day blanking period, were eligible. Patients were allocated to receive warfarin or 5 or 2.5 mg twice...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Authors: Kinoshita H, Kawahito S PMID: 29774736 [PubMed - as supplied by publisher]
Source: Minerva Anestesiologica - Category: Anesthesiology Tags: Minerva Anestesiol Source Type: research
CONCLUSIONS: In ACS patients, the rates of MACE and NACE were not significantly lower with bivalirudin than with UFH in both sexes.The rate of the composite of urgent TVR,definite ST,or NACE was not significantly lower with a post-PCI bivalirudin infusion than with no post-PCI infusion in both sexes. PMID: 29769167 [PubMed - as supplied by publisher]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
ConclusionsThe risk of the composite outcome of death, MI, stroke, or major bleeding at 2-year follow-up was significantly higher in TAVR patients treated with TT or SAC versus AP, even after multivariate adjustment.
Source: Cardiology and Therapy - Category: Cardiology Source Type: research
(MedPage Today) -- No increased risk of bleeding complications in Danish registry
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
(MedPage Today) -- But bleeding risk comes with the reduction in ischemic stroke, trial shows
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Bleeding | Brain | Germany Health | Marketing | Neurology | Pharmaceuticals | Stroke